Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Yannick, Vandenplas"'
Publikováno v:
Health Research Policy and Systems, Vol 21, Iss 1, Pp 1-11 (2023)
Abstract Background The Belgian government has taken several measures to increase the uptake of biosimilars in past years. However, no formal evaluation of the impact of these measures has been made yet. This study aimed to investigate the impact of
Externí odkaz:
https://doaj.org/article/c732f63592704398a8b73ea2a8aaa4f1
Autor:
Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto, Florian Turk, Isabelle Huys
Publikováno v:
BMC Health Services Research, Vol 22, Iss 1, Pp 1-17 (2022)
Abstract Background A competitive market for off-patent biologicals leads to more affordable and high-quality healthcare. In recent years, Belgium has been characterized by its low use of biosimilars and by its shifts from off-patent biologicals towa
Externí odkaz:
https://doaj.org/article/59e1fc16f9ed4505adf3bff497d1bc28
Autor:
Steven Simoens, Khadidja Abdallah, Liese Barbier, Teresa Barcina Lacosta, Alessandra Blonda, Elif Car, Zilke Claessens, Thomas Desmet, Evelien De Sutter, Laurenz Govaerts, Rosanne Janssens, Teodora Lalova, Evelien Moorkens, Robbe Saesen, Elise Schoefs, Yannick Vandenplas, Eline Van Overbeeke, Ciska Verbaanderd, Isabelle Huys
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Countries are struggling to provide affordable access to medicines while supporting the market entry of innovative, expensive products. This Perspective aims to discuss challenges and avenues for balancing health care system objectives of
Externí odkaz:
https://doaj.org/article/bbc0089204d243a890fa9366197ff0a6
Autor:
Yannick Vandenplas, Liese Barbier, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto, Isabelle Huys
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2022)
Background and objectives: Biosimilar medicines have been on the European market for 15 years. Despite the extensive and positive experience with biosimilars across Europe, their uptake remains limited in Belgium. One of the possible factors limiting
Externí odkaz:
https://doaj.org/article/dc5621398cce48eeaf008afdd0c8c935
Autor:
Liese Barbier, Yannick Vandenplas, Steven Simoens, Paul Declerck, Arnold G. Vulto, Isabelle Huys
Publikováno v:
Journal of Pharmaceutical Policy and Practice, Vol 14, Iss 1 (2021)
Background With the approval of biosimilars for subcutaneously administered products, such as adalimumab, etanercept and insulin, biosimilars become increasingly available in ambulatory care. Little is known about the knowledge and attitudes of healt
Externí odkaz:
https://doaj.org/article/f7e2ca842a8a4ae387b7e7e738cbe4aa
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background and objective: Best-value biological medicines may generate competition in the off-patent biologicals market, resulting in having more resources available to provide patients with access to necessary medicines while maintaining high-qualit
Externí odkaz:
https://doaj.org/article/982564a683eb4aa58b51a5c0dc2f3262
Publikováno v:
American Journal of Health-System Pharmacy, 79(22), 2001-2011. American Society of Health-Systems Pharmacy
Purpose With the growing availability of biosimilars on the global market, clinicians and pharmacists have multiple off-patent biological products to choose from. Besides the competitiveness of the product’s price, other criteria should be consider
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e479a5ad5b985baa5b3e7ae219fc5dfe
https://doi.org/10.1093/ajhp/zxac235
https://doi.org/10.1093/ajhp/zxac235
Publikováno v:
Pharmaceuticals, Vol 14, Iss 2, p 117 (2021)
Biosimilar medicines support the sustainability of national healthcare systems, by reducing costs of biological therapies through increased competition. However, their adoption into clinical practice largely depends on the acceptance of healthcare pr
Externí odkaz:
https://doaj.org/article/14ae4c6df6824d9684cec60116924995
BACKGROUND AND OBJECTIVE: Pharmaceutical policies are generally based on the assumption that involved stakeholders make rational decisions. However, behavioral economics has taught us that this is not always the case as people deviate from rational b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50cad130db03d0efddace630548d17e9
https://lirias.kuleuven.be/handle/20.500.12942/699964
https://lirias.kuleuven.be/handle/20.500.12942/699964
Publikováno v:
Applied health economics and health policy. 20(6)
Pharmaceutical policies are generally based on the assumption that involved stakeholders make rational decisions. However, behavioral economics has taught us that this is not always the case as people deviate from rational behavior in rather predicta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::634b30a97e128d23d2c7b6aecaa40085
https://pubmed.ncbi.nlm.nih.gov/35972683
https://pubmed.ncbi.nlm.nih.gov/35972683